Posterior tibial nerve stimulation for fecal incontinence: Where are we?

Anil Thomas George, Rudra Krishna Maitra, Charles Maxwell-Armstrong

Abstract

Neurostimulation remains the mainstay of treatment for patients with faecal incontinence who fails to respond to available conservative measures. Sacral nerve stimulation (SNS) is the main form of neurostimulation that is in use today. Posterior tibial nerve stimulation (PTNS) - both the percutaneous and the transcutaneous routes - remains a relatively new entry in neurostimulation. Though in its infancy, PTNS holds promise to be an effective, patient friendly, safe and cheap treatment. However, presently PTNS only appears to have a minor role with SNS having the limelight in treating patients with faecal incontinence. This seems to have arisen as the strong, uniform and evidence based data on SNS remains to have been unchallenged yet by the weak, disjointed and unsupported evidence for both percutaneous and transcutaneous PTNS. The use of PTNS is slowly gaining acceptance. However, several questions remain unanswered in the delivery of PTNS. These have raised dilemmas which as long as they remain unsolved can considerably weaken the argument that PTNS could offer a viable alternative to SNS. This paper reviews available information on PTNS and focuses on these dilemmas in the light of existing evidence.
on its use in improving the symptoms of FI as well as improving the quality of life of the patients\textsuperscript{[9]}. Posterior tibial nerve stimulation (PTNS) for faecal incontinence is relatively new with just under 20 studies being reported\textsuperscript{[3]}. PTNS has been used mainly in the management of urinary incontinence\textsuperscript{[8,9]}. Shafik et al\textsuperscript{[3]} has been credited with attempting PTNS for faecal incontinence. PTNS can be performed either by using a more invasive percutaneous approach\textsuperscript{[8]} where an inserted 34 gauge needle forms the route of stimulation or by the less invasive transcutaneous “Qualtero” approach\textsuperscript{[11]} where cutaneous pads replace the needle. Studies that have been done looking at the efficacy of the percutaneous PTNS approach are far more than those which have looked at the less invasive transcutaneous approach. Though there have been no studies so far which have directly compared these two routes of stimulation, indirect evidence points to a better efficacy for the percutaneous approach\textsuperscript{[11]}.

PTNS is usually delivered unilaterally, at the nerve’s most superficial position which lies just above and behind the medial malleolus. The area of the nerve stimulated is quite small as the grounding electrode is usually placed in the instep. No evidence exists as to any dominance of the left or right tibial nerve unlike the pudendal nerve\textsuperscript{[12]}.  

**DILEMMAS IN TREATMENT**

**Treatment protocols dilemmas**

There remains a lack of an effective and standardised treatment protocol for both percutaneous and transcutaneous PTNS (Table 1).  

Shafik et al\textsuperscript{[3]} in 2003 reported giving 30 min of percutaneous PTNS stimulation on alternate days for a period of four weeks. Though there is now a general consensus that patients require 12 wk of continuous treatment and that each treatment episode should last 30 min, there is no uniformity on how this should be given. Studies have given a single 30 min session of PTNS once a week for 12 wk while others have given two 30 min sessions a week for 6 wk\textsuperscript{[13-15]}. Three prospective studies of percutaneous PTNS from the same institution have used either once a week or twice a week patterns of treatment with no apparent differences in efficacy\textsuperscript{[16-18]}. The superiority of one approach over the other remains yet remains to be demonstrated. The National Institute of Clinical Excellence (NICE) suggests both patterns could be adapted depending on patient response\textsuperscript{[19,20]}. It is logical that the onset of symptom improvement for the patient will only occur later on into the treatment using the once a week regime compared to the twice a week regime. The once a week treatment can help alleviate hospital workloads and may be more acceptable to the patient. However, the onset of symptom improvement for the patient on a once a week regime could be delayed which may have a potential for more patient dropouts. All percutaneous PTNS studies so far have utilised unilateral stimulation. There remains the unexplored question as to whether bilateral percutaneous PTNS could be more effective given that a recent pilot study on bilateral transcutaneous PTNS has shown better efficacy compared to unilateral stimulation\textsuperscript{[14,20]}.

The same treatment protocol dilemma exists for transcutaneous PTNS as well. Queralto provided patients with unilateral daily stimulation for 20 min for 4 wk and showed an 80% improvement in incontinence severity scores\textsuperscript{[10]}. Eléouet et al\textsuperscript{[23]} reported 63% improvement following a 20 min of unilateral twice daily stimulation for 1 mo. Vitton et al\textsuperscript{[22,23]} attempted transcutaneous PTNS once daily for 3 mo on two groups of patients and reported a 41% and 54% improvement in symptoms. George et al attempted unilateral transcutaneous PTNS twice a week for 6 wk and reported a 45% improvement in symptoms\textsuperscript{[11]}. Leroi et al\textsuperscript{[20]} reported no improvements in the transcutaneous arm compared to the sham group following 20 min twice daily sessions for 3 mo. Thomas et al\textsuperscript{[25]} suggested in a pilot study that daily stimulation may offer a better response compared to a twice weekly regime. A more recent variation has been the application of transcutaneous PTNS as a daily bilateral stimulation for 6 wk which has been reported to be more effective than the unilateral approach\textsuperscript{[14,20]}. Only in one study was the transcutaneous PTNS stimulation provided in a hospital setting\textsuperscript{[11]} while all the other studies required patients to apply the stimulation themselves at home after being trained.

**Stimulation endpoint dilemmas**

The stimulation end point for the transcutaneous PTNS was to look for a motor response which was visualization of rhythmic flexion of toes during stimulation\textsuperscript{[11]}. Intensity of stimulation was then turned down to just below the threshold required for motor contraction. This seems to be a common end point for stimulation in most of the transcutaneous PTNS studies except the published RCT\textsuperscript{[11]} where a sensory and a motor response was sought and a study by Vitton et al\textsuperscript{[23]} where a sensory response was looked for.

However, the end point for stimulation for percutaneous PTNS remains uncharted with no specific end points described to confirm effective stimulation. Percutaneous PTNS can cause both a sensory and a motor response. The motor response is flexion of the big toe or fanning of all toes; the sensory response is a tingling sensation felt on the foot radiating to all of the toes\textsuperscript{[26]}. The original paper by Shafik et al\textsuperscript{[3]} looked for a motor response following stimulation. However, subsequent studies introduced a sensory response as an endpoint for stimulation\textsuperscript{[16-18]}. The voltage used and the intensity of stimulation to achieve a sensory response remains lower than the intensity required to achieve a motor response\textsuperscript{[28]}. This could imply that the voltage used for eliciting a sensory response alone could be sub-optimal without the full potential of the treatment being realised. This could in turn be reflected in lower treatment response rates.

Using the presence of either a motor or a sensory response could imply different treatment levels for differ-
ent patients. In addition, patients with diabetes mellitus or with peripheral neuropathy could have an impaired sensory response or none at all. The published RCT used the presence of both a motor and sensory response as the end point for effective stimulation\(^{11}\). The presence of a combined motor and sensory response on PTNS has been reported to be better associated with a successful outcome than the presence of either a motor or a sensory response alone\(^{23}\). However, this could cause patient discomfort as higher voltages required for achieving a motor response may have the potential to cause discomforting sensory stimulations in some patients. The CONFIDENT multicentre randomised controlled trial (ISRCTN 88559475) presently underway in the United Kingdom utilises either a sensory or a motor response as an endpoint for stimulation.

### Efficacy dilemmas

Percutaneous PTNS for FI remains a relatively new and untested treatment with only 12 studies, one randomised controlled trial\(^{11}\) and one review\(^{20}\) having been published to date on its use. The only published RCT on PTNS only reports on a 6 mo follow-up\(^{11}\). There remains no doubt regarding the short term efficacy of PTNS which are comparable to that of SNS. However, the true test of the effectiveness of PTNS would be its efficacy in the medium and long term. This is crucial as this could validate its effectiveness as a treatment option for faecal incontinence rather than a stepping stone towards SNS. There is a dearth of information on such results though

---

**Table 1** Posterior tibial nerve stimulation evidence summary \(a\) (%)

| Ref.          | Patient (\(n\)) | Type of PTNS | Time, frequency and duration of therapy | Follow-up | Stimulation endpoints | Efficacy | Study classification |
|---------------|-----------------|--------------|----------------------------------------|-----------|-----------------------|----------|----------------------|
| Shaﬁk et al\(^{10}\) | 32              | Pct          | 30 min, alternate days; 4 wk            | 22 mo     | Motor                 | 27 (84)  | Nonrandomised controlled |
| Queralto et al\(^{11}\) | 10              | Tct          | 20 min, daily; 4 wk                    | 4 mo      | Motor                 | 8 (80)   | Prospective controlled |
| Mentes et al\(^{12}\) | 2\(^1\) (spinal) | Pct          | 30 min, alternate days; 4 wk           | 3 mo      | Motor                 | 2 (100)  | Prospective controlled |
| Vittone et al\(^{13}\) | 12\(^2\) (IBD) | Tct          | 20 min, daily; 3 wk                    | 3 mo      | Sub sensory           | 5 (42)   | Prospective controlled |
| Babber et al\(^{14}\) | 8               | Pct          | 30 min, weekly; 3 wk                   | 3 mo      | Not specified         | 7 (87)   | Prospective controlled |
| De La Portella et al\(^{15}\) | 16             | Pct          | 30 min, weekly; 12 wk                  | 6 mo      | Motor and sensory     | 10 (62)  | Prospective controlled |
| Vittone et al\(^{16}\) | 24              | Tct          | 20 min, daily; 12 wk                   | 15 mo     | Sub sensory           | 13 (54)  | Prospective controlled |
| Govaert et al\(^{17}\) | 22              | Pct          | 30 min, twice weekly; 6 wk             | 12 mo     | Motor and/or sensory  | 18 (82)  | Prospective controlled |
| "Boyle et al\(^{18}\) | 31              | Pct          | 30 min, weekly; 12 wk                  | 14 mo     | Motor or sensory      | 21 (68)  | Prospective controlled |
| Findlay et al\(^{19}\) | 13              | Pct          | 30 min, weekly; 12 wk                  | 4 mo      | Sub motor             | 12 (92)  | Retrospective controlled |
| Eléouet et al\(^{20}\) | 32              | Tct          | 20 min, twice daily; 4 wk              | 6 mo      | Motor                 | 20 (63)  | Prospective controlled |
| "Allison\(^{21}\) | 90              | Pct          | 30 min, twice weekly or weekly; 6 wk or 12 wk | 21 mo | Motor or sensory     | 69 (77)  | Prospective controlled |
| "Hotouras et al\(^{22}\) | 100             | Pct          | 30 min, twice weekly or weekly; 6 wk or 12 wk | 6 mo     | Motor or sensory      | 85 (85)  | Prospective controlled |
| Leroi et al\(^{23}\) | 144             | Tct          | 20 min, twice daily; 3 mo              | 3 mo      | Sub motor             | 34 (47)  | Randomised controlled trial |
| George et al\(^{24}\) | 11              | Pct          | 30 min, twice weekly; 6 wk              | 6 mo      | Motor and sensory     | 9 (82)   | Randomised controlled trial |
| 11              | Tct          | 30 min, twice weekly; 6 wk              | 6 mo      | Motor and sensory     | 5 (45)   | Randomised controlled trial |
| Thomas et al\(^{25}\) | 15              | Tct          | 30 min, daily; 6 wk                    | 6 wk      | Sensory               | 3 (20)   | Prospective randomised |
| 15              | Tct          | 30 min, twice weekly; 6 wk              | 6 wk      | Sensory               | 0 (0)    |                       |
| Moreira et al\(^{26}\) | 10              | Pct          | 30 min, weekly; 12 wk                  | 3 mo      | Not specified         | 6 (60)   | Prospective controlled |
| "Hotouras et al\(^{27}\) | 150             | Pct          | 30 min, twice weekly or weekly; 3 mo   | 26 mo     | Motor or sensory      | 60 (52)  | Prospective controlled |

\(^{1}\)Study included spinal injury patients; \(^{2}\)Study included patients with inflammatory bowel disease (IBD); \(^{3}\)Studies from the same institution - possibility of duplication of results. PTNS: Posterior tibial nerve stimulation; Pct: Percutaneous posterior tibial nerve stimulation; Tct: Transcutaneous posterior tibial nerve stimulation.
early reports from Hotouras et al.\cite{15,16} who has published on the largest group of PTNS patients so far (n = 100) reports a possible sustained efficacy for PTNS after 42 mo of follow-up\cite{29}. However, this group\cite{16,18} provided percutaneous PTNS as the first line therapy for fecally incontinent patients without assessing whether they were refractory to other non-interventional treatments\cite{19}. This could perhaps imply that some of their patients would have had improvement in symptoms with other less invasive treatments had this been attempted. The CONFIDENT multicentre randomised controlled trial (ISRCTN 8855947) which is presently underway across 14 centres in the United Kingdom may shed more light on the true short term efficacy of PTNS though only the percutaneous approach is compared to a sham route of stimulation. Though this study recruits patients who have been refractory to other less invasive therapies, the lack of any form of standardisation nationally for such therapies nationally remains notable.

The efficacy of transcutaneous PTNS remains even more untested with only a handful of studies which have looked at this approach to PTNS. Though several studies have reported symptoms improvements in patients a recent multicentre trial reported no improvements following stimulation and concluded that unilateral transcutaneous PTNS was no more effective than sham stimulation\cite{24}. Patients were exposed to stimulation for 20 min twice daily for 3 mo\cite{24}. However, a new pilot study has looked at bilateral transcutaneous PTNS and found it to be effective compared to unilateral stimulation\cite{20}.

**FOLLOW-UP DILEMMAS**

There remain no standardised follow-up and top-up regimes that can be used for percutaneous and transcutaneous PTNS. Most studies report efficacy only at the end of the 6 or 12 wk treatment period. The first percutaneous PTNS study reported a relapse of symptoms in 29% of patients with the majority of patients improving with further treatment though the exact regime for such follow up treatment was not reported\cite{5}. Almost all studies on PTNS mention the need for “top-up” treatments. However there remains no clarity as to whether such top-up sessions should be offered only when patients report back due to recurrence of symptoms or whether such sessions should be offered at lengthening intermittent intervals after the intense initial treatment period. One study on percutaneous PTNS reported good efficacy with a median of one 12 monthly top-up session\cite{18}. Regular percutaneous PTNS top-ups at lengthening intermittent intervals resulted in a sustained therapeutic effect for urological dysfunction\cite{13}. New studies on PTNS make inroads into this aspect though this has to be verified through more independent trials\cite{19}.

The same dilemmas exist for transcutaneous PTNS as well. The efficacy following transcutaneous PTNS lasts for about 3 wk post treatment\cite{20}. Though there is no definite top-up regimes recommended there remains the advantage that such treatments can be undertaken by the patient in the comfort of their own homes as well as the fact that the costs for such top-ups will be very low\cite{20}.

In comparison to SNS where the treatment effects are short-lived following the withdrawal of treatment, PTNS appears to confer a slightly longer lasting effect (albeit with a declining efficacy). However, a recent study on SNS has shown persisting efficacy even after the device was switched off which may bring it to par with the longer effects of PTNS\cite{31}.

The heterogeneity of follow-up regimes for PTNS makes it difficult to assess exactly the long-term effects of its treatment. Furthermore, only a few studies have performed rigorous assessment of “top-up” regimes to maintain efficacy. Further work needs to be done on the follow-up of patients who benefit from PTNS to accurately assess the duration of efficacy.

**COST IMPLICATIONS**

The present worldwide financial crisis has thrown into stark view the cost implications of neurostimulation. The direct medical costs for PTNS remain nearly ten times cheaper than those for SNS\cite{37,32,35}. In PTNS itself the costs between percutaneous and transcutaneous PTNS also varies significantly. Percutaneous PTNS requires a re-usable stimulator 9V stimulator (Urgent PC®, Uroplasty Inc., United States) along with 12 disposable single-use leads. The disposable kits with 12 individually packed sterile stimulation units and a disposable battery for the Urgent PC stimulator unit costs £480 and are sufficient for the full treatment of 12 sessions\cite{26,30}. The cost for the Urgent PC stimulator unit (Uroplasty, Berkshire, United Kingdom) is £1000. However, the reusable nature of the stimulator unit can reduce the costs of multiple treatments.

The costs for transcutaneous PTNS remain even smaller with the 50 mm × 50 mm self-re-usable adhesive surface electrode stimulation pads (Model VS.5050; Premier Medical Products, Bedford, United Kingdom) costing £1 per pair. The stimulator unit used is the NeuroTrac Continence Neurostimulator (Verity Medical Ltd, United Kingdom) costs £80 and can be re-used as the percutaneous stimulator\cite{20}.

SNS involves the in-vivo implantation of highly advanced technological devices and both the temporary and permanent wires were implanted under general anaesthesia. The higher costs for SNS arise due to the two-stage procedure along with associated pre- and post-operative care. The equipment only costs of SNS (2008 tariffs) were £526 for the temporary implant and £13500 for the permanent implant\cite{32}. However, the actual charges levied for these procedures vary. Reports of costs for the initial temporary procedure for SNS vary from £1300\cite{33} to about £5300\cite{31}. Costs for the permanent implant procedure also varies from £14500\cite{31} to about £21200\cite{35}. Performing the initial stage of SNS under local analgesia appears to be more patient friendly and cheaper\cite{36,38}. 

George AT et al. Posterior tibial nerve stimulation
One of the underlying concerns regarding PTNS remains on the follow up treatment and the hidden costs for these which may outweigh the initial costs savings. Running an SNS service is expensive[39]. However, there remains the possibility that the costs for maintaining the efficacy of PTNS in patients may be higher as they remain yet unknown. Conflicting reports on the cost effectiveness of both procedures are available[7]. A two-year follow up of percutaneous PTNS in patients with faecal incontinence from one center reported that PTNS became cost effective after the first year of treatment[33]. However, another study which compared SNS to PTNS at 5 years post treatment for urological dysfunction reported that SNS therapy became much more cost efficient compared to PTNS[49]. Unlike SNS, running costs and long term follow up expenses for PTNS lacks clarity given the absence of a uniform and universally accepted follow up protocol along with the dearth of independent medium and long term follow up data on “successfully” treated PTNS patients.

Future for PTNS?

There remains no question that SNS is less patient friendly and more expensive than PTNS in the short term[33]. Early attempts to make SNS more patient friendly have experimented at less invasive forms of SNS administration using a transcutaneous Percutaneous PTNS though minimally invasive does not require any operative procedures or a hospital inpatient stay. Patients also do not require a 3 wk trial phase which presently exists for SNS with insertion of a temporary SNS wire and a permanent implant subsequently if successful. Percutaneous PTNS has the potential to be delivered through a primary care setting using perhaps the abilities of specialist nurses who could provide these services on an outpatient basis. This could drive the costs of PTNS down even further.

Transcutaneous PTNS has the unique potential of being a treatment which is truly “by the patient, for the patient”. FI can be socially crippling with patients sometimes being unwilling to leave the safety of their own homes for fear of incontinent episodes[61]. Transcutaneous PTNS may hold promise as a treatment which patients can self-administer safely, cheaply and effectively in the comfort of their own homes[40].

Presently PTNS appears to have the role as a stepping stone towards SNS in patients with faecal incontinence. Efficacy of transcutaneous PTNS has been used as a predictor for suggesting efficacy of SNS[22]. However, the question remains as to why patients should choose a potentially less patient friendly and clinicians should offer a more expensive and invasive treatment in the form of SNS when PTNS is available-albeit, in its infancy. This seems to have arisen as the strong, coherent, uniform and evidence based data on SNS remains to have been unchallenged yet by the weak, incoherent, disjointed and unsupported evidence for PTNS. A pilot study comparing SNS and percutaneous PTNS (UKCRN ID 10479/ MREC ID 10/11 0808/38) may help shed more light on direct comparison between the two treatments.

The true role for PTNS remains yet to be validated and time tested - as SNS has been. However, the question as to whether SNS and PTNS become “brothers in arms” in treating FI or whether this may yet turn out to be the “David vs Goliath” battle will be answered only once PTNS has come into its prime.

REFERENCES

1. Jarrett ME, Dudding TC, Nicholls RJ, Vaizey CJ, Cohen CR, Kamm MA. Sacral nerve stimulation for fecal incontinence related to obstetric anal sphincter damage. Dis Colon Rectum 2008; 51: 531-537 [PMID: 18301948 DOI: 10.1007/s10350-008-9199-2]
2. Jarrett ME, Mowatt G, Glazener CM, Fraser C, Nicholls RJ, Grant AM, Kamm MA. Systematic review of sacral nerve stimulation for faecal incontinence and constipation. Br J Surg 2004; 91: 1559-1569 [PMID: 15455360 DOI: 10.1002/bjs.4796]
3. NICE. Sacral nerve stimulation for faecal incontinence. Interventional Procedure Guidance 99. In: Excellence NLoC, editor. London: National Institute of Clinical Excellence, 2004
4. Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 1995; 346: 1124-1127 [PMID: 7475602]
5. Shafik A, Ahmed I, El-Sibai O, Mostafa RM. Percutaneous peripheral neuromodulation in the treatment of faecal incontinence. Eur Surg Res 2003; 35: 103-107 [PMID: 12679620]
6. Tan E, Ngo NT, Darzi A, Shendonu M, Tekkis PP. Meta-analysis: sacral nerve stimulation versus conservative therapy in the treatment of faecal incontinence. Int J Colorectal Dis 2011; 26: 275-294 [PMID: 21279370 DOI: 10.1007/s00384-010-1119-y]
7. Falletto E. Invited comment on Hultén et al.: Sacral nerve stimulation (SNS), posterior tibial nerve stimulation (PTNS) or acupuncture for the treatment for fecal incontinence: a clinical commentary. Tech Coloproctol 2013; 17: 593-595 [PMID: 23754345 DOI: 10.1007/s10151-013-1011-1]
8. Nakamura M, Sakurai T, Tsujimoto Y, Tada Y. [Transcutaneous electrical stimulation for the control of frequency and urge incontinence]. Hinyokika Kiyo 1983; 29: 1053-1059 [PMID: 6610298]
9. McGuire EJ, Zhang SC, Horwinski ER, Lytton B. Treatment of motor and sensory detrusor instability by electrical stimulation. ]Urol 1983; 129: 78-79 [PMID: 6600794]
10. Queraltto M, Portier G, Cabarrot PH, Bonnau G, Chatard JP, Nadrigmy N, Lazorthes F. Preliminary results of peripheral transcutaneous neuromodulation in the treatment of idiopathic fecal incontinence. Int J Colorectal Dis 2006; 21: 670-672 [PMID: 16331464 DOI: 10.1007/s00384-005-0068-3]
11. George AT, Kalmar K, Sala S, Kopanakis K, Panarese A, Dudding TC, Hollingshead JR, Nicholls RJ, Vaizey CJ. Randomized controlled trial of percutaneous versus transcutaneous posterior tibial nerve stimulation in faecal incontinence. Br J Surg 2013; 100: 330-338 [PMID: 23300071 DOI: 10.1002/bjs.9000]
12. Hamdy S, Enck P, Aziz Q, Uenggoerl G, Holson A, Thompson DG. Laterality effects of human pudendal nerve stimulation on corticoanal pathways: evidence for functional asymmetry. Gut 1999; 45: 58-63 [PMID: 10369705]
13. Staskin DR, Peters KM, MacDiarmid S, Shore N, de Groat WC. Percutaneous tibial nerve stimulation: a clinically and cost effective addition to the overactive bladder algorithm of care. Curr Urol Rep 2012; 13: 327-334 [PMID: 22893501 DOI: 10.1007/s11934-012-0274-9]
George AT et al. Posterior tibial nerve stimulation

14 Thomas TDGP, Bradshaw E, Nicholls RJ, Vaizey CJ. Development of an optimum treatment regimen for transcutaneous posterior tibial nerve stimulation for faecal incontinence. Colorectal Dis 2013; 15 (S1): 6

15 Hotouras A, Thaha MA, Boyle DJ, Allison ME, Currie A, Knowles CH, Chan CL. Short-term outcome following percutaneous tibial nerve stimulation (PTNS) for faecal incontinence: does it last? Colorectal Dis 2013; 15 (S1): 11

16 Hotouras A, Thaha MA, Boyle DJ, Allison ME, Currie A, Knowles CH, Chan CL. Percutaneous tibial nerve stimulation for patients with faecal incontinence. Nurs Stand 2011; 25: 44-48 [PMID: 21417180 DOI: 10.7748/nrs2011.02.25.44.e8343]

17 Boyle DJ. Prosser K, Allison ME, Williams NS, Chan CL. Percutaneous tibial nerve stimulation for the treatment of urge fecal incontinence. Dis Colon Rectum 2010; 53: 432-437 [PMID: 20305443 DOI: 10.1007/DCR.0b013e3181752747]

18 NIC. Interventional procedure overview of percutaneous tibial nerve stimulation for faecal incontinence (IPG 395). In: NIC, editor. London, 2011

19 Thomas GP, Dudding TC, Nicholls RJ, Vaizey CJ. Bilateral transcutaneous posterior tibial nerve stimulation for the treatment of fecal incontinence. Dis Colon Rectum 2013; 56: 1075-1079 [PMID: 23929017 DOI: 10.1097/DCR.0b013e31829b9f40]

20 Eflouet M, Siproudhis L, Guilou N, Le Coadic J, Bouguen G, Bregtane JF. Chronic posterior tibial nerve transcutaneous electrical nerve stimulation (TENS) to treat fecal incontinence (FI). Int J Colorectal Dis 2010; 25: 1127-1132 [PMID: 20549220 DOI: 10.1007/s00384-010-0960-3]

21 Vitton V, Damon H, Roman S, Nancey S, Flourié B, Mion F. Transcutaneous posterior tibial nerve stimulation for fecal incontinence in inflammatory bowel disease patients: a therapeutic option? Inflamm Bowel Dis 2009; 15: 402-405 [PMID: 18972550 DOI: 10.1002/ibd.20774]

22 Vitton V, Damon H, Roman S, Mion F. Transcutaneous electrical posterior tibial nerve stimulation for faecal incontinence: effects on symptoms and quality of life. Int J Colorectal Dis 2010; 25: 1017-1020 [PMID: 20524002 DOI: 10.1007/s00384-010-0962-1]

23 Leroi AM, Ciapetti L, Elieeney I, Damon H, Zerbib F, Amarencos G, Vitton V, Faucheron JL, Thomas C, Mion F, Roumeigue P, Gourcerol G, Bouvier M, Lalouche K, Menard JF, Queraltó M. Transcutaneous electrical tibial nerve stimulation in the treatment of fecal incontinence: a randomized trial (CONSORT 1a). Am J Gastroenterol 2012; 107: 1888-1896 [PMID: 23032981 DOI: 10.1038/ajg.2012.330]

24 Thomas GP, Dudding TC, Bradshaw E, Nicholls RJ, Vaizey CJ. A pilot study to compare daily with twice weekly transcutaneous posterior tibial nerve stimulation for faecal incontinence. Colorectal Dis 2013; 15: 1504-1509 [PMID: 24189972 DOI: 10.1111/codi.12428]

25 George AT, Vaizey CJ. Percutaneous posterior tibial nerve stimulation for fecal incontinence: are we all reading from the same page? Dis Colon Rectum 2013; 56: e328-e330 [PMID: 23652761 DOI: 10.1097/DCR.0b013e318286f6d4]

26 George A, Panarese A, Sala S, Kalmar K, Kokopoulis K, Nicholls R, Vaizey CJ. Predictive factors for percutaneous tibial nerve stimulation for fecal incontinence. Gastroenterology 2011; 60(Suppl 1): A157 [DOI: 10.1113/gut.2011.329013.333]

27 Thomas GP, Dudding TC, Rahbour G, Nicholls RJ, Vaizey CJ. A review of posterior tibial nerve stimulation for faecal incontinence. Colorectal Dis 2013; 15: 519-526 [PMID: 23216902 DOI: 10.1111/codi.12093]

28 Hotouras A, Allison M, Chan CL. The authors reply. Dis Colon Rectum 2013; 56: e329-e330 [PMID: 23652762 DOI: 10.1097/DCR.0b013e318286f6ee]
Findlay JM, Yeung JM, Robinson R, Greaves H, Maxwell-Armstrong C. Peripheral neuromodulation via posterior tibial nerve stimulation - a potential treatment for faecal incontinence? Ann R Coll Surg Engl 2010; 92: 385-390 [PMID: 20626970 DOI: 10.1308/003588410X12628812459652]

Moreira SPS, Batista M, Silveira F, Correia da Silva P, Parad da F, Costa Maia J. Percutaneous tibial nerve stimulation for treatment of fecal incontinence. International Continence Society Annual Conference. Barcelona, Spain: International Continence Society, 2013: Abstract 891

P- Reviewers: El-Nashar SA, Santoro GA
S- Editor: Wen LL
L- Editor: A
E- Editor: Ma S
